Literature DB >> 30760112

Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials.

Emily Carl1, Sara M Witcraft2, Brooke Y Kauffman3, Eilis M Gillespie4, Eni S Becker5, Pim Cuijpers6, Michael Van Ameringen7, Jasper A J Smits1, Mark B Powers1,8.   

Abstract

The purpose of this meta-analysis was to provide updated pooled effect sizes of evidence-based psychotherapies and medications for generalized anxiety disorder (GAD) and to investigate potential moderators of outcomes. Seventy-nine randomized controlled trials (RCT) including 11,002 participants with a diagnosis of GAD were included in a meta-analysis that tested the efficacy of psychotherapies or medications for GAD. Psychotherapy showed a medium to large effect size (g = 0.76) and medication showed a small effect size (g = 0.38) on GAD outcomes. Psychotherapy also showed a medium effect on depression outcomes (g = 0.64) as did medications (g = 0.59). Younger age was associated with a larger effect size for psychotherapy (p < 0.05). There was evidence of publication bias in psychotherapy studies. This analysis found a medium to large effect for empirically supported psychotherapy interventions on GAD outcomes and a small effect for medications on GAD outcomes. Both groups showed a medium effect on depression outcomes. Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly. Patient age should be further investigated as a potential moderator in psychotherapy outcomes in GAD.

Entities:  

Keywords:  GAD; generalized anxiety disorder; medication; meta-analysis: randomized controlled trial; therapy

Year:  2019        PMID: 30760112      PMCID: PMC7063818          DOI: 10.1080/16506073.2018.1560358

Source DB:  PubMed          Journal:  Cogn Behav Ther        ISSN: 1650-6073


  92 in total

1.  Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.

Authors:  S Duval; R Tweedie
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

4.  Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

Authors:  A J Gelenberg; R B Lydiard; R L Rudolph; L Aguiar; J T Haskins; E Salinas
Journal:  JAMA       Date:  2000-06-21       Impact factor: 56.272

5.  Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial.

Authors:  Melinda A Stanley; Nancy L Wilson; Diane M Novy; Howard M Rhoades; Paula D Wagener; Anthony J Greisinger; Jeffrey A Cully; Mark E Kunik
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

6.  Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial.

Authors:  Falk Leichsenring; Simone Salzer; Ulrich Jaeger; Horst Kächele; Reinhard Kreische; Frank Leweke; Ulrich Rüger; Christel Winkelbach; Eric Leibing
Journal:  Am J Psychiatry       Date:  2009-07-01       Impact factor: 18.112

7.  Cognitive-behavioral treatment of late-life generalized anxiety disorder.

Authors:  Melinda A Stanley; J Gayle Beck; Diane M Novy; Patricia M Averill; Alan C Swann; Gretchen J Diefenbach; Derek R Hopko
Journal:  J Consult Clin Psychol       Date:  2003-04

8.  A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder.

Authors:  David Hackett; Vincent Haudiquet; Eliseo Salinas
Journal:  Eur Psychiatry       Date:  2003-06       Impact factor: 5.361

9.  Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.

Authors:  Ronald C Kessler; Maria Petukhova; Nancy A Sampson; Alan M Zaslavsky; Hans-Ullrich Wittchen
Journal:  Int J Methods Psychiatr Res       Date:  2012-08-01       Impact factor: 4.035

10.  Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Karla J Alaka; William Noble; Angel Montejo; Héctor Dueñas; Autar Munshi; Jeffrey R Strawn; Alan Lenox-Smith; Jonna Ahl; Leszek Bidzan; Brita Dorn; Susan Ball
Journal:  Int J Geriatr Psychiatry       Date:  2014-02-20       Impact factor: 3.485

View more
  14 in total

1.  The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.

Authors:  Falk Leichsenring; Christiane Steinert; Sven Rabung; John P A Ioannidis
Journal:  World Psychiatry       Date:  2022-02       Impact factor: 49.548

Review 2.  Treatment of Mental Health in Patients With Chronic Liver Disease.

Authors:  Thomas G Cotter; Thomas Beresford
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-05-23

3.  Determining the Efficacy of Electronic Cognitive Behavioral Therapy for Generalized Anxiety Disorder Compared to Pharmaceutical Interventions: Protocol for a Quasi-Experimental Study.

Authors:  Nazanin Alavi; Callum Stephenson; Megan Yang; Amirhossein Shirazi; Yijia Shao; Anchan Kumar; Caitlin S Yee; Shadé Miller; Anthi Stefatos; Maedeh Gholamzadehmir; Zara Abbaspour; Archana Patel; Charmy Patel; Taras Reshetukha; Mohsen Omrani; Dianne Groll
Journal:  JMIR Res Protoc       Date:  2021-05-27

Review 4.  The effectiveness of Internet-delivered treatment for generalized anxiety disorder: An updated systematic review and meta-analysis.

Authors:  Nora Eilert; Angel Enrique; Rebecca Wogan; Olwyn Mooney; Ladislav Timulak; Derek Richards
Journal:  Depress Anxiety       Date:  2020-11-22       Impact factor: 6.505

5.  Thigmotaxis in a virtual human open field test.

Authors:  Daniel Gromer; Dominik P Kiser; Paul Pauli
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

Review 6.  The role of brain gaseous neurotransmitters in anxiety.

Authors:  Artur Pałasz; Itiana Castro Menezes; John J Worthington
Journal:  Pharmacol Rep       Date:  2021-03-13       Impact factor: 3.024

7.  Evaluation of an Augmented Cognitive Behavioural Group Therapy for Perinatal Generalized Anxiety Disorder (GAD) during the COVID-19 Pandemic.

Authors:  Sheryl M Green; Briar Inness; Melissa Furtado; Randi E McCabe; Benicio N Frey
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

Review 8.  Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science.

Authors:  Emily A Holmes; Rory C O'Connor; V Hugh Perry; Irene Tracey; Simon Wessely; Louise Arseneault; Clive Ballard; Helen Christensen; Roxane Cohen Silver; Ian Everall; Tamsin Ford; Ann John; Thomas Kabir; Kate King; Ira Madan; Susan Michie; Andrew K Przybylski; Roz Shafran; Angela Sweeney; Carol M Worthman; Lucy Yardley; Katherine Cowan; Claire Cope; Matthew Hotopf; Ed Bullmore
Journal:  Lancet Psychiatry       Date:  2020-04-15       Impact factor: 27.083

9.  Internet-Delivered Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Nationwide Routine Care: Effectiveness Study.

Authors:  Ville Ritola; Jari Olavi Lipsanen; Satu Pihlaja; Eero-Matti Gummerus; Jan-Henry Stenberg; Suoma Saarni; Grigori Joffe
Journal:  J Med Internet Res       Date:  2022-03-24       Impact factor: 7.076

10.  Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report.

Authors:  Dan J Stein; Alan E Kazdin; Ayelet Meron Ruscio; Wai Tat Chiu; Nancy A Sampson; Hannah N Ziobrowski; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Yasmin Altwaijri; Ronny Bruffaerts; Brendan Bunting; Giovanni de Girolamo; Peter de Jonge; Louisa Degenhardt; Oye Gureje; Josep Maria Haro; Meredith G Harris; Aimee Karam; Elie G Karam; Viviane Kovess-Masfety; Sing Lee; Maria Elena Medina-Mora; Jacek Moskalewicz; Fernando Navarro-Mateu; Daisuke Nishi; José Posada-Villa; Kate M Scott; Maria Carmen Viana; Daniel V Vigo; Miguel Xavier; Zahari Zarkov; Ronald C Kessler
Journal:  BMC Psychiatry       Date:  2021-08-09       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.